Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.1%

2 terminated out of 33 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

9%

3 trials in Phase 3/4

Results Transparency

33%

8 of 24 completed with results

Key Signals

8 with results92% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (1)
P 1 (14)
P 2 (7)
P 3 (2)
P 4 (1)

Trial Status

Completed24
Not Yet Recruiting2
Terminated2
Recruiting2
Unknown1
Suspended1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT03877926Phase 3CompletedPrimary

VELOCITY: An Anthrax Vaccine Clinical Study

NCT00050310RecruitingPrimary

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

NCT05997264Phase 2Active Not RecruitingPrimary

Anthrax AV7909 Boost Evaluation Study

NCT03569514Not Yet RecruitingPrimary

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

NCT07268612Not Yet RecruitingPrimary

Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

NCT04067011Phase 2CompletedPrimary

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT01753115Phase 2CompletedPrimary

Ciprofloxacin BioThrax Co-Administration Study

NCT04660201Phase 1CompletedPrimary

Anthrax AV7909 Liquid vs Lyophilized

NCT06365073RecruitingPrimary

A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

NCT01491607Phase 3CompletedPrimary

Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

NCT01770743Phase 2CompletedPrimary

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

NCT00845650Phase 1CompletedPrimary

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

NCT01202695Phase 1CompletedPrimary

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

NCT05672875TerminatedPrimary

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

NCT03088111Phase 4Unknown

An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

NCT01624532Phase 2CompletedPrimary

A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

NCT04148118Phase 1CompletedPrimary

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

NCT04320485CompletedPrimary

Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)

NCT03518125Phase 2CompletedPrimary

BARDA Securing Anthrax Immunity For the Elderly

NCT03498027Completed

Febrile Whole Blood Specimen Collection and Testing

Scroll to load more

Research Network

Activity Timeline